Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recurrent low-grade glioma (IGG) and select a molecule …

2023年2月23日 · Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in a perioperative...

2020年6月12日 · We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with m IDH1 solid tumors. Ivosidenib was administered orally daily in 28-day cycles. In 66 patients with advanced gliomas, ivosidenib was well tolerated, with no dose-limiting toxicities reported.

Background: Ivosidenib, a small-molecule IDH inhibitor is FDA approved for relapsed or refractory acute myeloid leukemia and cholangiocarcinoma with IDH1 mutation. Early phase clinical trials have shown promising findings for IDH mutant gliomas and results of larger studies of IDH inhibitors in gliomas are still pending.

2024年7月19日 · The recently published INDIGO trial, demonstrating the benefit of the mutant IDH inhibitor vorasidenib in patients with low-grade IDH-mutant gliomas, introduces a new era of precision medicine in...

2024年12月19日 · Ivosidenib, an oral, brain-penetrant inhibitor of IDH1, was the first IDHi evaluated in patients with IDHm glioma. 4 In a phase I trial from 2014 to 2019, ivosidenib demonstrated a favorable safety profile, prolonged disease control relative to historical controls, and decreased growth rate in nonenhancing tumors (although it did not show ...

2024年5月29日 · Ivosidenib (AG-120), a second-generation IDH inhibitor, is an FDA approved medication for treatment of IDH-mutated acute myeloid leukemia and has demonstrated safety and clinical activity in patients with progressive IDH mutant gliomas. We explored the efficacy of Ivosidenib in IDH mutant gliomas.

2024年12月19日 · Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel targeted approach for treating IDHm glioma patients, yet their optimal use in clinical practice outside of clinical trials remains undefined. This study describes real-world utilization of the mutant IDH1 inhibitor (IDHi), ivosidenib, in patients with IDHm glioma.

Ongoing trials are investigating the role of IDH inhibitors in solid tumors, including gliomas. Here, we present the first case study of a patient with a recurrent IDH1 -mutant GBM who had radiographic stable disease for over 4 years and improved seizure control while treated with the IDH1 inhibitor ivosidenib.

2024年11月11日 · Ivosidenib offers a novel targeted therapy for non-enhancing IDH1 mutated gliomas following initial resection. Potential effects of IDH inhibitors on enhancing disease in clinical settings are not well established.